Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder - A 12-week prospective, open-label, randomized, parallel-group trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Lee, Bun-Hee | - |
dc.contributor.author | Ko, Young-Hoon | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Joe, Sook-Haeng | - |
dc.contributor.author | Jung, In-Kwa | - |
dc.date.accessioned | 2021-09-09T16:47:21Z | - |
dc.date.available | 2021-09-09T16:47:21Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 1173-2563 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/125606 | - |
dc.description.abstract | Objective: We set out to compare the efficacy and tolerability of mirtazapine versus venlafaxine in patients with undifferentiated somatoform disorder (USD) using the Patient Health Questionnaire-15 (PHQ-15). Methods: This was a 12-week prospective, open-label, randomized, parallel-group trial. The trial consisted of six visits that included baseline and weeks 1, 2, 4, 8 and 12. The primary effectiveness measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ) from baseline to the end of treatment. Ninety-five subjects were randomized to either mirtazapine (n =50) or venlafaxine (n = 45); 71 subjects completed the study (mirtazapine: n=39/50 [78%]; venlafaxine: n = 32/45 [71%]). Results: The mean total score on the PHQ-15 decreased by 34.7% (-8.4, p < 0.0001) from baseline to endpoint in the mirtazapine group and by 26.6% (-6.1, p < 0.0001) in the venlafaxine group. A marginally significant between-group difference was observed for the mean change in total score on the PHQ-15 from baseline to endpoint (F = 4.126, p = 0.046). The mean total scores on the GHQ-12 and BDI from baseline to endpoint decreased by -4.9 (29.4%, p < 0.0001) and -13.5 (55.9%, p < 0.0001), respectively, in the mirtazapine group, and by -4.3 (26.2%, p = 0.001) and -9.02 (46.0%, p < 0.0001), respectively, in the venlataxine group. No between-group difference was observed for the mean changes in total scores on the secondary effectiveness measures from baseline to endpoint. Both treatments were well tolerated. Conclusion: Our findings suggest that both mirtazapine and venlafaxine may be effective and well tolerated in the treatment of patients with USD. Double-blind, placebo-controlled and/or head-to-head comparison studies are required to allow definite conclusions to be drawn. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ADIS INT LTD | - |
dc.subject | POSTTRAUMATIC-STRESS-DISORDER | - |
dc.subject | GENERALIZED ANXIETY DISORDER | - |
dc.subject | PRIMARY-CARE PATIENTS | - |
dc.subject | EXTENDED-RELEASE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | UNEXPLAINED SYMPTOMS | - |
dc.subject | SOMATIC COMPLAINTS | - |
dc.subject | PANIC DISORDER | - |
dc.subject | CHRONIC PAIN | - |
dc.subject | PLACEBO | - |
dc.title | Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder - A 12-week prospective, open-label, randomized, parallel-group trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.contributor.affiliatedAuthor | Ko, Young-Hoon | - |
dc.identifier.doi | 10.2165/00044011-200828040-00006 | - |
dc.identifier.scopusid | 2-s2.0-40949123518 | - |
dc.identifier.wosid | 000254865900007 | - |
dc.identifier.bibliographicCitation | CLINICAL DRUG INVESTIGATION, v.28, no.4, pp.251 - 261 | - |
dc.relation.isPartOf | CLINICAL DRUG INVESTIGATION | - |
dc.citation.title | CLINICAL DRUG INVESTIGATION | - |
dc.citation.volume | 28 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 251 | - |
dc.citation.endPage | 261 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | POSTTRAUMATIC-STRESS-DISORDER | - |
dc.subject.keywordPlus | GENERALIZED ANXIETY DISORDER | - |
dc.subject.keywordPlus | PRIMARY-CARE PATIENTS | - |
dc.subject.keywordPlus | EXTENDED-RELEASE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | UNEXPLAINED SYMPTOMS | - |
dc.subject.keywordPlus | SOMATIC COMPLAINTS | - |
dc.subject.keywordPlus | PANIC DISORDER | - |
dc.subject.keywordPlus | CHRONIC PAIN | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordAuthor | Mirtazapine, therapeutic use | - |
dc.subject.keywordAuthor | Somatoform disorders | - |
dc.subject.keywordAuthor | Venlafaxine, therapeutic use | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.